Latest news with #Larimar
Yahoo
30-07-2025
- Business
- Yahoo
Larimar Therapeutics Announces Pricing of Underwritten Public Offering
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. ('Larimar') (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 18,750,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to Larimar from this offering are expected to be $60.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Larimar. The offering is expected to close on or about July 31, 2025, subject to the satisfaction of customary closing conditions. Leerink Partners, Guggenheim Securities, Truist Securities and William Blair are acting as joint bookrunning managers for the offering. Larimar intends to use the net proceeds from the proposed offering to support the development of nomlabofusp and other pipeline candidates, and for working capital and general corporate purposes, including research and development expenses and pre-commercialization expenses. The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-279275) that was declared effective by the Securities and Exchange Commission ('SEC') on May 24, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on July 29, 2025 and is available for free on the SEC's website at A final prospectus supplement with the final terms of the offering and accompanying prospectus will be filed with the SEC and will be available for free on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105 or by email at syndicate@ Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, New York 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@ Truist Securities, Inc., Attention: Equity Capital Markets, 740 Battery Ave SE, Atlanta, Georgia 30339, by telephone at (800) 685-4786 or by email at or William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, Illinois 60606, by telephone at (800) 621-0687 or by email at prospectus@ This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction. About Larimar Therapeutics, Inc. Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. Caution Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'may,' 'might,' 'will,' 'should,' 'believe,' 'expect,' 'anticipate,' 'estimate,' 'continue,' 'predict,' 'forecast,' 'project,' 'plan,' 'intend,' or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of Larimar's management. Such forward-looking statements include, without limitation, statements relating to the completion, use of proceeds and anticipated total gross proceeds from the public offering of common stock. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering, and other risks and uncertainties related to the public offering, as well as the risks and uncertainties set forth in the 'Risk Factors' section and elsewhere in the prospectus supplement related to the public offering filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission and available at including but not limited to Larimar's periodic reports, including Larimar's most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Larimar assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law. Investor Contact:Joyce Allaire LifeSci Advisors jallaire@ (212) 915-2569 Company Contact: Michael CelanoChief Financial Officermcelano@ 414-2715Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-06-2025
- Business
- Yahoo
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia
Conference call and webcast on Monday, June 23, 2025 at 8:00 am EDT BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a conference call and webcast to discuss regulatory updates for the Company's nomlabofusp clinical development program for the treatment of Friedreich's Ataxia on Monday, June 23, 2025 at 8:00 am EDT. Conference Call and Webcast DetailsTo access the webcast on Monday, June 23, 2025 at 8:00 am EDT, please visit this link to the event. To participate by phone, please dial 1-877-407-9716 (domestic) or 1-201-493-6779 (international) and refer to conference ID 13754491 or click on this link and request a return call. Following the live event, an archived webcast will be available on the 'Events & Presentations' page of the Larimar website. About Larimar TherapeuticsLarimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: Forward-Looking StatementsThis press release contains forward-looking statements that are based on Larimar's management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar's ability to develop and commercialize nomlabofusp and any other planned product candidates, Larimar's planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions and filings with the FDA, expectations regarding potential for accelerated approval or accelerated access and time to market and overall development plans and other matters regarding Larimar's business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'intend,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'ongoing' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar's product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later clinical trials, and assessments; that the FDA may not ultimately agree with Larimar's nomlabofusp development strategy; the potential impact of public health crises on Larimar's future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar's ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp's manufacturing process; Larimar's ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar's ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar's ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar's periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar's management's views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law. Investor Contact:Joyce AllaireLifeSci Advisorsjallaire@ 915-2569 Company Contact:Michael CelanoChief Financial Officermcelano@ 414-2715Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Time Business News
20-06-2025
- Entertainment
- Time Business News
Discover The Tranquil Charm Of Larimar Jewelry
There's something nearly magical about wearing a bit of the sea to your skin—cool, calming, and undeniably charming. That's exactly the experience you get whilst you wear Larimar Jewelry. This isn't just another gemstone you toss in a drawer or overlook in a container. Larimar has a soul-soothing electricity and a one-of-a-type appearance that makes it a should-have for all and sundry who craves splendor with intensity. Whether or now not you're a crystal lover, a style fanatic, or someone who just appreciates the healing vibe of nature, Larimar is a gem that appears like a deep breath in your spirit. Allow's dive into what makes this gemstone so precise, why it's all of sudden trending everywhere, and why you might need to consider including a chunk to your series—like, proper now. Imagine shooting the gentle blues of Caribbean waters and the mild swirls of clouds in a single stone. That's the herbal splendor of Larimar. Located only inside the Dominican Republic, this uncommon blue form of pectolite is as different as it's far captivating. It's now not just rare in terms of location; the mining method isn't any stroll on the beach either. Larimar is pulled from deep, narrow mines in mountainous terrain, including a layer of difficult-earned authenticity to every piece. What genuinely units it aside, although, is the emotional connection people sense with it. Larimar is often associated with calmness, readability, and conversation. It's like the ocean's solution to tension—mild and flowing, yet effective in its personal proper. No surprise it's on occasion known as the 'Stone of Atlantis.' In terms of everyday wear, Larimar earrings are like that at ease sweater that still occurs to make you look elegant. You don't wear it to face out—you wear it to sense like your excellent, maximum grounded self. Whether or not or not it is a dainty pendant, a bold cuff bracelet, or a statement earring, each piece feels like a personal talisman of calm and energy. However, right here's the kicker: Larimar is so flexible that it appears simply as true with a white linen dress as it does along with your preferred jeans and tee. The gentle ocean colours are diffused sufficient for daywear but carry ample man or woman to raise a nighttime look. And it doesn't scream for interest—rather, it gently attracts humans in. Think quiet confidence in place of loud glamour. Even the texture performs a role in its charm. Most Larimar is polished smooth, which gives it a tactile fine that's particularly comforting to touch. It's the form of a piece you'll discover yourself absentmindedly rubbing for the duration of worrying moments, like a herbal strain ball made stunning. There's something exceedingly intimate, approximately a Larimar Ring. It's no longer dangling out of your neck or swaying out of your ears—it's proper there on your hand, part of your everyday motions, usually within your sightline. And that steady presence brings its calming electricity directly into your everyday habit. Many Larimar jewelry are set in sterling silver, which pairs flawlessly with the cool tones of the stone. The designs variety from minimalist to elaborate, because of this there's something for each taste. Whether or not you choose a solitaire stone that speaks for itself or an in depth setting with filigree artwork, you'll find that a Larimar ring constantly seems greater than simply an accessory. It looks like a mild reminder to gradual down, breathe, and discover your center. It also makes for a remarkable present—suppose birthdays, anniversaries, or just-due to the fact moments. Larimar isn't simply quiet to study; it's soaked in which means. For folks who are into the metaphysical international, Larimar is assumed to activate the throat chakra, promoting clean verbal exchange and emotional launch. It's regularly utilized in meditation to get admission to deeper emotional perception and foster serenity. Even in case you don't purchase into the religious side of crystals, you may't deny the emotional impact of color and shape. The moment you have a look at Larimar, you sense a shift. Like a sunny day after consistent weeks of rain, it uplifts and facilitates you. In an international that feels increasingly rapid-paced and chaotic, carrying something that brings balance and calm isn't simply fashionable—it's vital. No longer is all Larimar created equal. If you're idea of investing in a piece, ensure it's actual. The colour should range from light to sky blue, often with white marbling or swirling patterns. The extra vibrant the blue, the rarer—and normally more expensive—the piece. It's additionally essential to supply from professional sellers. You need to recognise that the stone was ethically mined and that you're getting true Larimar, no longer a dyed imitation. Honest jewelers will offer data on starting place and great, and plenty of provide certifications of authenticity. And at the same time as you're buying, don't be surprised if one piece just speaks to you. Larimar has a funny method of selecting its wearer. The one you maintain coming back to? That's probably the one you have been meant to have. Lifestyles busy. Your to-do listing is long, the notifications never forestall, and stress is just a part of the deal. But wearing a piece of Larimar rings is like carrying a touch pocket of paradise with you. It's a mild reminder to respire, gradual down, and reconnect with what virtually subjects. Style-smart, it's timeless. Emotionally, it's grounding. And spiritually, it's a powerful companion. So whether or not you're eyeing a graceful Larimar ring or a declaration necklace, recognize which you're now not just choosing out jewelry. You're inviting calm, clarity, and natural splendor into your ordinary existence. And virtually? That's a vibe worth investing in. TIME BUSINESS NEWS
Yahoo
21-05-2025
- Business
- Yahoo
Larimar Therapeutics, Inc.'s (LRMR): Analysts See 957% Upside Potential
We recently published an article titled . Larimar Therapeutics, Inc. (NASDAQ:LRMR) was one of the stocks that was covered in that article. Wall Street analysts believe LRMR has a 957% upside potential over the next 12 months. Closeup shot of a scientist in a lab coat examining a microscope for breakthroughs in biotechnology. Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a biotechnology company focused on developing innovative treatments for rare genetic disorders. Among its pioneering efforts is the development of Nomlabofusp (CTI-1601), a therapeutic candidate specifically designed to address Friedreich's ataxia (FA). This rare and progressive genetic disorder stems from insufficient levels of frataxin, a mitochondrial protein essential for proper cellular function. By delivering frataxin to affected cells, Nomlabofusp aims to target the core deficit of FA, offering hope for improved cellular health and a potential slowing of disease progression. Central to Larimar's scientific approach is its proprietary intracellular delivery platform. This technology enables therapeutic molecules to cross cell membranes effectively, opening new possibilities for addressing other rare diseases marked by similar deficiencies or intracellular dysfunctions. The company continues to explore and expand its pipeline, leveraging this platform to address unmet needs in the realm of rare diseases. This forward-thinking strategy positions Larimar as a leader in developing transformative therapies in the biotechnology sector. In December of last year, the company disclosed that two patients experienced serious adverse events related to its experimental therapy, nomlabofusp, a treatment for Friedreich's ataxia (FA. This lead to a decline in the company's share price by 30% in intra-day trading. Larimar Therapeutics, however, maintains a strong financial foundation. The company's Q1 2025 earnings report highlighted its solid financial position with $157.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025. This financial stability provides the resources necessary to sustain research and development activities and bolster commercialization efforts. Furthermore, Larimar projects its cash runway to extend well into the second quarter of 2026, ensuring continued progress in its clinical programs. Analysts have taken note of Larimar's promising trajectory, expressing confidence in the company's potential for growth. With an upside of 957.52%, the stock's estimated twelve-month price projection stands at $20.04, reflecting optimism about the potential impact of the company's groundbreaking work. Through its innovative technologies, strategic focus, and financial resilience, Larimar Therapeutics is advancing solutions that may redefine the treatment of rare diseases for patients worldwide. Overall, Larimar Therapeutics, Inc. (NASDAQ:LRMR) ranks 2nd on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of LRMR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LRMR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
21-05-2025
- Business
- Yahoo
Larimar Therapeutics, Inc.'s (LRMR): Analysts See 957% Upside Potential
We recently published an article titled . Larimar Therapeutics, Inc. (NASDAQ:LRMR) was one of the stocks that was covered in that article. Wall Street analysts believe LRMR has a 957% upside potential over the next 12 months. Closeup shot of a scientist in a lab coat examining a microscope for breakthroughs in biotechnology. Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a biotechnology company focused on developing innovative treatments for rare genetic disorders. Among its pioneering efforts is the development of Nomlabofusp (CTI-1601), a therapeutic candidate specifically designed to address Friedreich's ataxia (FA). This rare and progressive genetic disorder stems from insufficient levels of frataxin, a mitochondrial protein essential for proper cellular function. By delivering frataxin to affected cells, Nomlabofusp aims to target the core deficit of FA, offering hope for improved cellular health and a potential slowing of disease progression. Central to Larimar's scientific approach is its proprietary intracellular delivery platform. This technology enables therapeutic molecules to cross cell membranes effectively, opening new possibilities for addressing other rare diseases marked by similar deficiencies or intracellular dysfunctions. The company continues to explore and expand its pipeline, leveraging this platform to address unmet needs in the realm of rare diseases. This forward-thinking strategy positions Larimar as a leader in developing transformative therapies in the biotechnology sector. In December of last year, the company disclosed that two patients experienced serious adverse events related to its experimental therapy, nomlabofusp, a treatment for Friedreich's ataxia (FA. This lead to a decline in the company's share price by 30% in intra-day trading. Larimar Therapeutics, however, maintains a strong financial foundation. The company's Q1 2025 earnings report highlighted its solid financial position with $157.5 million in cash, cash equivalents, and marketable securities as of March 31, 2025. This financial stability provides the resources necessary to sustain research and development activities and bolster commercialization efforts. Furthermore, Larimar projects its cash runway to extend well into the second quarter of 2026, ensuring continued progress in its clinical programs. Analysts have taken note of Larimar's promising trajectory, expressing confidence in the company's potential for growth. With an upside of 957.52%, the stock's estimated twelve-month price projection stands at $20.04, reflecting optimism about the potential impact of the company's groundbreaking work. Through its innovative technologies, strategic focus, and financial resilience, Larimar Therapeutics is advancing solutions that may redefine the treatment of rare diseases for patients worldwide. Overall, Larimar Therapeutics, Inc. (NASDAQ:LRMR) ranks 2nd on our list of 13 Best Multibagger Stocks to Invest in Now. While we acknowledge the potential of LRMR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LRMR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: 10 Best Low Volatility Stocks to Buy Now and Starter Stock Portfolio: 12 Safe Stocks to Buy Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
